Getting patients vaccinated matters more than which COVID-19 vaccine they receive, says Jodi Longueil, PharmD.
|Articles|August 31, 2022
Daily OTC Pearl: Backaid Max
Author(s)Saro Arakelians, PharmD
Backaid Max offers relief of backaches, leg and joint pain.
Advertisement
OTC/Lifestyle Pearl of the Day: Backaid Max
Indication: Backaid Max offers relief of backaches, leg and joint pain.
Insight:
- Non-drowsy, caffeine- and aspirin-free.
- Dual-relief formula offers relief from pain and discomfort from fluid build-up.
- Contains acetaminophen 500 mg.
- Pamabrom 25 mg.
- Take 2 capsules every 6 hours as needed.
- Keep away from children.
Source:
Advertisement
Related to this article
The new agreement lets Hims & Hers patients obtain FDA-approved tirzepatide and orforglipron at Lilly’s self-pay prices.
The approval is supported by findings from the phase 3 OCEANIC-STROKE trial.
Pharmacists can plan career sabbaticals before retirement with smart savings, employer leave options, and intentional steps that balance their finances with their goals.
Christie Ballantyne, MD, explains how the CORALreef Extension study adds safety exposure and shows LDL-C lowering with oral enlicitide is sustained over time.
Like enzymes and coenzymes, monitoring devices and pharmacists may achieve more together than either can alone.
The glucagon/GLP-1 dual agonist did not raise major adverse cardiovascular event risk in adults with obesity, but GI-related discontinuations were high.
Post hoc AHA 2026 data show the oral GLP-1 receptor agonist lowered systolic blood pressure across hypertension stages, partly beyond weight loss.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Requires Class-Wide GLP-1 RA Labeling Changes for Potential NAION Risk
2
Asundexian Receives FDA Approval, Becomes First FXIa Inhibitor for Secondary Stroke Risk Reduction
3
mRNA vs Protein-Based COVID-19 Vaccines: What Pharmacists Can Tell Patients
4
Oral PCSK9 Inhibitor Enlicitide Sustains LDL-C Reductions
5